-
Sanofi Strengthens STAT6 Pipeline with Nurix
Sanofi
Sanofi expands its collaboration with Nurix by licensing NX-3911, a potent STAT6 degrader targeting inflammatory diseases. The deal includes $15M upfront and up to $465M in milestones, with Nurix retaining U.S. co-development rights.
博乐市|
通化市|
镇原县|
彝良县|
稻城县|
舞钢市|
天镇县|
博罗县|
河津市|
榕江县|
榆树市|
康定县|
泗洪县|
察雅县|
敖汉旗|
小金县|
阳曲县|
方城县|
类乌齐县|
韶关市|
密云县|
永新县|
巴塘县|
互助|
胶南市|
曲麻莱县|
青阳县|
罗定市|
广河县|
彭水|
邳州市|
仙桃市|
大新县|
松潘县|
治多县|
青铜峡市|
康保县|
乌审旗|
岱山县|
黄浦区|
镇平县|